Tuberculosis (TB) has remained a public health problem worldwide with greater incidence in low- and middle-income countries.[1] One out of every 3 persons is expected to be infected with this airborne bacterium viz. Mycobacterium tuberculosis (the causative agent for TB), and 5-15% of these persons develop active TB disease in their lifetime.[2] TB commonly involves the lungs however; it can affect any part of the body and therefore is responsible for a substantial amount of morbidity and mortality among those who are affected.[2] It has an adverse effect on patients’ psychology, and economic and social well-being which ultimately has a negative impact on the quality of life (QoL). [3] For the control of TB in India, Government of India initiated DOTS program in 1998. DOTS include administration of isoniazid, rifampicin, pyrazinamide and ethambutol are used for 2 months during the intensive phase and followed by administration of isoniazid and rifampicin for 4 months during continuation phase